Evidence map›Paper›PMID 28544236›Full record

ArticleJournal of thrombosis and haemostasis : JTH2017

Clinical and laboratory phenotype variability in type 2M von Willebrand disease.

A L Doruelo, S L Haberichter, P A Christopherson, L N Boggio, S Gupta, S R Lentz, A D Shapiro, R R Montgomery, V H Flood

Abstract read
In one paragraph

Article in Journal of thrombosis and haemostasis : JTH, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Application of genetic testing for the diagnosis of von Willebrand disease.Journal of thrombosis and haemostasis : JTH · 2024
    Review
  4. von Willebrand disease.Nature reviews. Disease primers · 2024
    Review
  5. Article
  6. Laboratory variability in the diagnosis of type 2 VWD variants.Journal of thrombosis and haemostasis : JTH · 2021
    Article
  7. Article
  8. Current issues in diagnosis and treatment of von Willebrand disease.Research and practice in thrombosis and haemostasis · 2018
    Review
  9. Combined effects of two mutations in von Willebrand disease 2M phenotype.Research and practice in thrombosis and haemostasis · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

A L DorueloDepartment of Pediatrics, Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
S L HaberichterDepartment of Pediatrics, Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
P A ChristophersonBlood Research Institute, BloodCenter of Wisconsin, Milwaukee, WI, USA.
L N BoggioRush University Medical Center, Chicago, IL, USA.
S GuptaIndiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA.
S R LentzUniversity of Iowa Carver College of Medicine, Iowa City, IA, USA.
A D ShapiroIndiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA.
R R MontgomeryDepartment of Pediatrics, Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
V H FloodDepartment of Pediatrics, Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.

Funding

Zimmerman Program for the Molecular and Clinical Biology of VWDP01HL081588 · NHLBI · VERSITI WISCONSIN, INC. · PI MONTGOMERY, ROBERT R · 2005 to 2016
$19.3M
Zimmerman Program on the Biology of VWDP01HL144457 · NHLBI · VERSITI WISCONSIN, INC. · PI MONTGOMERY, ROBERT R · 2019 to 2023
$13.3M
Comparative Effectiveness in the Diagnosis of VWDR01HL112614 · NHLBI · VERSITI WISCONSIN, INC. · PI ABSHIRE, THOMAS CALVIN, MONTGOMERY, ROBERT R · 2013 to 2018
$4.1M
Molecular Interactions of FVIII and VWFR01HL139847 · NHLBI · VERSITI WISCONSIN, INC. · PI MONTGOMERY, ROBERT R · 2018 to 2021
$2.3M
Mechanism of Type 4 Collagen Interactions with Von Willebrand FactorR01HL126810 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI FLOOD, VERONICA H · 2016 to 2020
$1.9M
Functional Implications of VWF A1 Domain PolymorphismsK08HL102260 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI FLOOD, VERONICA H · 2010 to 2014
$662k
NHLBI NIH HHS K08 HL102260NHLBI NIH HHS P01 HL081588NHLBI NIH HHS P01 HL144457NHLBI NIH HHS R01 HL112614NHLBI NIH HHS R01 HL126810NHLBI NIH HHS R01 HL139847
6 · The paper itself

Abstract

Essentials The pathophysiology of type 2M von Willebrand disease (VWD) is poorly understood. Sequence variations in type 2M VWD subjects were characterized. A high degree of clinical and laboratory variability exists within type 2M VWD variants. Some type 2M variants may share features of type 2A VWD. SUMMARY: Background von Willebrand factor (VWF) is a multimeric coagulation factor that tethers platelets to injured subendothelium. Type 2M von Willebrand disease (VWD) is characterized by a qualitative defect in VWF with preserved multimer distribution. Objectives Through the Zimmerman Program for the Molecular and Clinical Biology for VWD, five VWF sequence variations were studied in subjects diagnosed with type 2M VWD. Methods Bleeding phenotype was assessed using the ISTH bleeding assessment tool. Full-length VWF gene sequencing was performed for each subject. Each variant was placed into a recombinant VWF vector using site-directed mutagenesis and expressed in HEK293T cells as homozygous or heterozygous VWF. Variant expression, collagen binding and platelet GPIbα binding were studied through ELISA assays. Multimer analysis was performed by gel electrophoresis. Results Bleeding scores were elevated for all subjects except for the p.P1162L and p.R1374C variants. Although all had reduced VWF ristocetin cofactor activity/VWF antigen ratios on plasma testing, recombinant VWF did not show a classic type 2M phenotype for any of the five variants. Homozygous expression of variants p.D1283Y, p.R1349C, p.R1374C and p.I1453N was consistent with type 2A VWD, although all had normal expression as heterozygous recombinant VWF. Variant p.P1162L had normal VWF expression and function, consistent with the lack of bleeding symptoms. Conclusions Although originally classified as type 2M VWD, these homozygous recombinant VWF variants do not fulfill complete 2M VWD diagnostic criteria. A better classification schema and improved testing for putative type 2M variants is needed in order to effectively diagnose and treat affected patients.

Indexed as

Genetic VariationAdultAged, 80 and overBlood CoagulationCase-Control StudiesCollagenFemaleGenetic Predisposition to DiseaseHEK293 CellsHemorrhageHeterozygoteHomozygoteHumansMaleMiddle AgedPedigreeadhesion receptorCollagenPlatelet Glycoprotein GPIb-IX Complexvon Willebrand Factorclinical laboratory techniqueshemorrhageplateletsvon Willebrand diseasevon Willebrand factor

Identifiers

PMID28544236
PMCPMC5538962

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.